xBxBio
xBxBio is a healthcare technology company focused on transforming cardiac care and drug discovery through AI-driven platforms. Their flagship product, Cardiologist-in-a-Box™, integrates high-resolution EKG and Holter data, patient-specific EMRs, imaging, and AI predictive modeling to provide real-time diagnostic, predictive, and prescriptive insights for cardiac patients. The platform mimics a world-class cardiologist's diagnostic reasoning, offering early detection of arrhythmias and myocardial risks with over 90% specificity and sensitivity. xBxBio also develops a physics, chemistry, biology, and mathematics-based SaaS platform to accelerate drug discovery by predicting molecular properties, reducing costs, and increasing success rates in clinical development. The company is led by experts with extensive experience in medicine, technology, and regulatory systems, including a National Medal of Technology recipient and former FDA executives. Their business model is SaaS, targeting healthcare providers and drug discovery teams, aiming to improve patient outcomes and reduce healthcare resource waste.
xBxBio
xBxBio is a healthcare technology company focused on transforming cardiac care and drug discovery through AI-driven platforms. Their flagship product, Cardiologist-in-a-Box™, integrates high-resolution EKG and Holter data, patient-specific EMRs, imaging, and AI predictive modeling to provide real-time diagnostic, predictive, and prescriptive insights for cardiac patients. The platform mimics a world-class cardiologist's diagnostic reasoning, offering early detection of arrhythmias and myocardial risks with over 90% specificity and sensitivity. xBxBio also develops a physics, chemistry, biology, and mathematics-based SaaS platform to accelerate drug discovery by predicting molecular properties, reducing costs, and increasing success rates in clinical development. The company is led by experts with extensive experience in medicine, technology, and regulatory systems, including a National Medal of Technology recipient and former FDA executives. Their business model is SaaS, targeting healthcare providers and drug discovery teams, aiming to improve patient outcomes and reduce healthcare resource waste.